Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$86.31M$86.31Mderived+30.5% vs Q4 2023 Net Income$9.59M$9.59MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$4,050,000N/M Operating Cash Flowderived$24,365,000+31.1% Free Cash Flowderived$16,798,000+13.5% Margins · derivedOperating margin4.7%+13.2 pt vs Q4 2023
Net margin11.1%+15.0 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end